These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 26883305)
1. Cannabis use in people with severe mental illness: The association with physical and mental health--a cohort study. A Pharmacotherapy Monitoring and Outcome Survey study. Bruins J; Pijnenborg MG; Bartels-Velthuis AA; Visser E; van den Heuvel ER; Bruggeman R; Jörg F J Psychopharmacol; 2016 Apr; 30(4):354-62. PubMed ID: 26883305 [TBL] [Abstract][Full Text] [Related]
2. The adverse health effects of chronic cannabis use. Hall W; Degenhardt L Drug Test Anal; 2014; 6(1-2):39-45. PubMed ID: 23836598 [TBL] [Abstract][Full Text] [Related]
3. Cannabinoids and psychosis. Sewell RA; Ranganathan M; D'Souza DC Int Rev Psychiatry; 2009 Apr; 21(2):152-62. PubMed ID: 19367509 [TBL] [Abstract][Full Text] [Related]
4. Course of cannabis use and clinical outcome in patients with non-affective psychosis: a 3-year follow-up study. van der Meer FJ; Velthorst E; Psychol Med; 2015 Jul; 45(9):1977-88. PubMed ID: 25654244 [TBL] [Abstract][Full Text] [Related]
5. Metabolic syndrome in people with a psychotic illness: is cannabis protective? Waterreus A; Di Prinzio P; Watts GF; Castle D; Galletly C; Morgan VA Psychol Med; 2016 Jun; 46(8):1651-62. PubMed ID: 26965714 [TBL] [Abstract][Full Text] [Related]
6. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness]. Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM; Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369 [TBL] [Abstract][Full Text] [Related]
7. Co-occurrence across time and space of drug- and cannabinoid- exposure and adverse mental health outcomes in the National Survey of Drug Use and Health: combined geotemporospatial and causal inference analysis. Reece AS; Hulse GK BMC Public Health; 2020 Nov; 20(1):1655. PubMed ID: 33148213 [TBL] [Abstract][Full Text] [Related]
8. Effects of cannabis use on body mass, fasting glucose and lipids during the first 12 months of treatment in schizophrenia spectrum disorders. Scheffler F; Kilian S; Chiliza B; Asmal L; Phahladira L; du Plessis S; Kidd M; Murray RM; Di Forti M; Seedat S; Emsley R Schizophr Res; 2018 Sep; 199():90-95. PubMed ID: 29519756 [TBL] [Abstract][Full Text] [Related]
9. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample. Winstock A; Lynskey M; Borschmann R; Waldron J J Psychopharmacol; 2015 Jun; 29(6):698-703. PubMed ID: 25759401 [TBL] [Abstract][Full Text] [Related]
10. Different psychological effects of cannabis use in adolescents at genetic high risk for schizophrenia and with attention deficit/hyperactivity disorder (ADHD). Hollis C; Groom MJ; Das D; Calton T; Bates AT; Andrews HK; Jackson GM; Liddle PF Schizophr Res; 2008 Oct; 105(1-3):216-23. PubMed ID: 18768298 [TBL] [Abstract][Full Text] [Related]
12. Perceived risk associated with tobacco, alcohol and cannabis use among people with and without psychotic disorders. Thornton LK; Baker AL; Johnson MP; Lewin T Addict Behav; 2013 Jun; 38(6):2246-51. PubMed ID: 23507458 [TBL] [Abstract][Full Text] [Related]
13. Cigarette smoking may modify the association between cannabis use and adiposity in males. Dubé E; O'Loughlin J; Karp I; Jutras-Aswad D Pharmacol Biochem Behav; 2015 Aug; 135():121-7. PubMed ID: 26026899 [TBL] [Abstract][Full Text] [Related]
14. Cannabis abuse and severity of psychotic and affective disorders in Israeli psychiatric inpatients. Katz G; Durst R; Shufman E; Bar-Hamburger R; Grunhaus L Compr Psychiatry; 2010; 51(1):37-41. PubMed ID: 19932824 [TBL] [Abstract][Full Text] [Related]
15. Health behaviour beliefs and physical health risk factors for cardiovascular disease in an outpatient sample of consumers with a severe mental illness: a cross-sectional survey. Brunero S; Lamont S Int J Nurs Stud; 2010 Jun; 47(6):753-60. PubMed ID: 19959166 [TBL] [Abstract][Full Text] [Related]
16. Characteristics of Synthetic Cannabinoid and Cannabis Users Admitted to a Psychiatric Hospital: A Comparative Study. Shalit N; Barzilay R; Shoval G; Shlosberg D; Mor N; Zweigenhaft N; Weizman A; Krivoy A J Clin Psychiatry; 2016 Aug; 77(8):e989-95. PubMed ID: 27379411 [TBL] [Abstract][Full Text] [Related]
17. Stopping cannabis use benefits outcome in psychosis: findings from 10-year follow-up study in the PAFIP-cohort. Setién-Suero E; Neergaard K; Ortiz-García de la Foz V; Suárez-Pinilla P; Martínez-García O; Crespo-Facorro B; Ayesa-Arriola R Acta Psychiatr Scand; 2019 Oct; 140(4):349-359. PubMed ID: 31381129 [TBL] [Abstract][Full Text] [Related]
18. Cannabis--psychosis pathway independent of other types of psychopathology. Ferdinand RF; van der Ende J; Bongers I; Selten JP; Huizink A; Verhulst FC Schizophr Res; 2005 Nov; 79(2-3):289-95. PubMed ID: 16125368 [TBL] [Abstract][Full Text] [Related]
19. Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial. Clausen L; Hjorthøj CR; Thorup A; Jeppesen P; Petersen L; Bertelsen M; Nordentoft M Psychol Med; 2014 Jan; 44(1):117-26. PubMed ID: 23590927 [TBL] [Abstract][Full Text] [Related]
20. A community survey of adverse effects of cannabis use. Thomas H Drug Alcohol Depend; 1996 Nov; 42(3):201-7. PubMed ID: 8912803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]